On 20-22 March, the Johnson & Johnson Innovation team arrived in Barcelona for this year’s BIO-Europe Spring®, Europe’s premier partnering conference for the biotech industry. Attracting 2,500+ biotech, pharma and finance leaders from around the world, BIO-Europe Spring® provides the ideal environment to engage with global life science partners in more than 15,000 partnering meeting opportunities over the three days.
Day one got off to a great start, with three of our colleagues taking the podium at various speaker engagement opportunities. Johnson & Johnson Innovation’s Sonal Patel, VP of Oncology Scientific Innovation, participated in a workshop entitled “Clinical Trials in Early Stage Oncology Development”. The discussion focused on how partnerships with hospital research networks in early stage oncology trials can contribute to scientific success and future collaboration at later stages.
Rick Davis, Senior Director of New Ventures & Transactions, took to the podium in the “Diversifying Risk with a Portfolio Strategy” panel. The session covered the pros and cons of streamlining a portfolio to focus resources on therapies with the greatest chance of success from specialisation in big pharma to repurposing identified compounds. Philippe Alen, Senior Director of Transactions at Janssen Business Development, presented an overview of Johnson & Johnson Innovation and specifically how Janssen Business Development emphasises the importance of collaboration for fostering innovation.
Philippe Alen, Senior Director of Transactions at Janssen Business Development; Sonal Patel, VP of Oncology Scientific Innovation, Johnson & Johnson Innovation; Rick Davis, Senior Director of New Ventures & Transactions, Johnson & Johnson Innovation
Day two was equally as busy, with the 3rd Johnson & Johnson Innovation-sponsored Startup Slam taking place in the afternoon! 14 shortlisted European start-ups pitched their innovation for transformative healthcare solutions live on stage to an exclusive judging panel of biotech leaders and a packed room of attendees. Following a tense wait for the judges’ decision, Peptomyc SL was crowned the Startup Slam Pitching Champ for their innovation targeting anti-Myc peptides for the treatment of cancer. The Peptomyc team, based in Barcelona, is set to receive mentorship from Johnson & Johnson Innovation as well as complimentary registration to the upcoming BIO-Europe® on 6-8 November in Berlin.
Laura Soucek, co-founder and CEO of Peptomyc, receiving her award
With speaker engagements and pitching competitions out of the way, day three was all about rounding up partnering activities. We had over 500 meeting requests during BIO-Europe Spring® and were able to take part in 231. In addition to the standard closed meeting room, our open-plan room was open for further conversations and meetings. Attendees were invited to come and #MaketheConnection and hear first-hand why innovation is at the heart of everything we do.
All in all, BIO-Europe Spring® was a huge success and we’re looking forward to progressing the many conversations and connections made into fruitful collaborations. We’re now counting down the days to Berlin!